Quantcast
Last updated on April 18, 2014 at 17:24 EDT

Latest Aromatase inhibitor Stories

2008-12-15 15:09:00

SAN ANTONIO, Dec. 15 /PRNewswire/ -- Two leading cancer physicians and researchers affiliated with US Oncology Research gave oral presentations at the 2008 San Antonio Breast Cancer Symposium. Three others presented their research in poster presentations during the conference, which ran December 10 through 14. Dr. Stephen Jones, US Oncology medical director and co-chair of its breast cancer research committee, presented findings on the largest of the three major trials comparing...

2008-12-15 00:04:38

Dense breast tissue contains more cells believed to give rise to breast cancer, compared to non-dense tissue, U.S. researchers said. Dr. Karthik Ghosh, a Mayo Clinic breast cancer researcher, said researchers found a dramatic difference in tissue composition between dense and non-dense tissue in the breast. In a second study, Celine Vachon, also of the Mayo Clinic, found that dense breast tissue has more aromatase enzyme than non-dense tissue. This is significant because aromatase helps...

2008-12-13 10:00:00

SAN ANTONIO, Dec. 13 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced findings from a European study demonstrating that the Oncotype DX Recurrence Score(R) result is a significant independent predictor of distant recurrence in both node-negative and node-positive, hormone receptor-positive breast cancer patients who are treated with the aromatase inhibitor anastrozole or with tamoxifen. Researchers from the Royal Marsden Hospital in London discussed results...

4b3e72cebb10b5e28129246061fd573f1
2008-12-12 14:38:05

According to a preliminary study reported Thursday at a cancer conference in Texas, new research adds fresh hope that a drug that strengthens bones might also fight breast cancer.  Women who were given the drug, Zometa, as part of their initial treatment had greater tumor shrinkage and were less likely to need radical surgery. Doctors were stunned in June when a big study found that Zometa, given previously to prevent bone loss caused by certain cancer treatments, also greatly cut the...

a171770fc779d62de5c3fb063c6fa3841
2008-11-13 08:49:02

Scientists in the UK published a study on Wednesday claiming they have figured out why some women develop resistance to the most commonly used breast cancer drug, something that raises the risk their tumors will return. Jason Carroll of Cancer Research UK in Cambridge, who led the study published in the journal Nature, said the findings could lead to new tests to determine which women are not likely to benefit from tamoxifen and who should be given other drugs. Carroll said the information...

2008-09-30 03:00:04

London, UK, and Cambridge, MA: 30 September 2008 - Cancer drug developer Antisoma plc (LSE: ASM; USOTC: ATSMY) today announced that it has started a phase II trial evaluating the addition of AS1402 to the endocrine (hormonal) therapy letrozole in post-menopausal women receiving first-line treatment for advanced breast cancer. Approximately 110 patients will be randomly assigned to receive either letrozole plus AS1402 or standard treatment with letrozole alone. The safety of the...

2008-09-25 09:00:16

EMERYVILLE, Calif., Sept. 25 /PRNewswire-FirstCall/ -- Bionovo, Inc. will present an abstract in a presentation on their new drug candidate, VG101, for the treatment of vaginal dryness, at the 19th Annual Meeting of the North American Menopause Society in Orlando, Florida on September 26, 2008. Dr. Mary Tagliaferri, president and chief medical officer of Bionovo, will provide seminal information on the company's second estrogen receptor beta selective drug candidate that will be entering...

2008-09-24 18:00:40

A predictive measurement -- preoperative endocrine prognostic index, or PEPI score -- may help women choose breast cancer treatment, U.S. researchers said. Researchers led by Dr. Matthew Ellis of Washington University developed and validated the PEPI score. "At present about 83 percent of patients are cured of breast cancer," Ellis said in a statement. "The key is to identify that 83 percent so we can treat them with effective available therapies and focus our research efforts on the 17...

2008-08-13 06:00:18

By Liz Szabo Women who survive five years after being diagnosed with breast cancer have a good chance of remaining cancer-free, a new study shows. In the most detailed study of its kind, the report shows that 89% of such patients remain disease-free 10 years after diagnosis, and 81% are cancer-free after 15 years. Authors of the study, published online Tuesday in the Journal of the National Cancer Institute, say their findings may reassure breast cancer survivors, many of whom...

2008-07-17 09:00:19

ANN ARBOR, Mich., July 17 /PRNewswire/ -- Meditrina Pharmaceuticals, Inc. today announced the approval of its second investigational new drug (IND) application for a Phase IIb dose ranging clinical trial to study MPI-676, the Company's aromatase inhibitor (AI), in combination with estrogen and progestin for the treatment of endometriosis. MPI-676 is the newest addition to Meditrina's clinical stage product portfolio that currently includes Femathina(TM) (MPI-674), an AI that Meditrina is...